表紙
市場調査レポート

慢性閉塞性肺疾患(COPD) - パイプライン製品の分析

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264708
出版日 ページ情報 英文 607 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
慢性閉塞性肺疾患(COPD) - パイプライン製品の分析 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 607 Pages
概要

慢性閉塞性肺疾患(COPD)は、肺からの呼気・吸気が不完全となり、息切れを引き起こす肺疾患です。肺への空気の流出入が阻害され、咳、疲労感、胸痛といった症状が 時間とともに悪化し、合併症も増加します。第一のリスク要因は喫煙ですが、化学物質や大気汚染などもCOPDの進行要因となります。進行は、禁煙やその他の治療薬投与により抑制されることがあります。

当レポートでは、慢性閉塞性肺疾患(COPD)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性閉塞性肺疾患(COPD)の概要

治療薬の開発

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

治療薬の評価

パイプライン製品の最新動向

開発が休止されている製品

開発が中止されている製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7688IDB

Summary

Global Markets Direct's, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016', provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)
  • The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Chronic Obstructive Pulmonary Disease (COPD) Overview
  • Therapeutics Development
    • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies
    • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes
    • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance
    • Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies
    • Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes
    • Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
    • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
  • Drug Profiles
    • Chronic Obstructive Pulmonary Disease (COPD) - Recent Pipeline Updates
    • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
    • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
    • Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2016
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Abeona Therapeutics, Inc. , H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alchemia Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ario Pharma Ltd, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asubio Pharma Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corporation, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotie Therapies Corp., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dong Wha Pharma Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Elsalys Biotech SAS, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by enGene, Inc, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics, LLC, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by InMed Pharmaceuticals Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Innate Pharma S.A., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Merck & Co., Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corporation, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Nivalis Therapeutics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novabiotics Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Odan Laboratories Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Panmira Pharmaceuticals, LLC., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Peptinnovate Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by PharmaLundensis AB, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Polyphor Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ProMetic Life Sciences Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteostasis Therapeutics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmagen Therapeutics LLP, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Re-Pharm Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Recipharm AB, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respira Therapeutics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by rEVO Biologics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SkyePharma Plc, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stelic Institute & Co., Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synovo GmbH, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Therabron Therapeutics, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theraclone Sciences, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance Biopharma, Inc., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Limited, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Unizyme Laboratories A/S, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vectura Group Plc, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by vTv Therapeutics LLC, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corporation, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Zambon Company S.p.A., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Recent Pipeline Updates, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..1), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..2), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..3), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..4), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..5), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..6), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..7), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..8), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..9), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..10), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..11), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..12), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..13), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..14), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..15), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..16), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..17), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..18), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..19), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..20), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..21), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..1), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..2), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..3), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..4), H1 2016
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..5), H1 2016

List of Figures

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2016
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top